108 related articles for article (PubMed ID: 12820423)
61. Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein-Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Assis MG; Silva JM; Dobo C; Oliveira JS
Med Oncol; 2012 Sep; 29(3):2148-52. PubMed ID: 21922298
[TBL] [Abstract][Full Text] [Related]
62. Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma.
Campos AH; Vassallo J; Soares FA
PLoS One; 2013; 8(9):e74793. PubMed ID: 24086377
[TBL] [Abstract][Full Text] [Related]
63. [Expression of matrix metalloproteinases in metastatic lesions of cutaneous squamous cell carcinoma].
Chen X; Kanekura T; Zhang GY
Hunan Yi Ke Da Xue Xue Bao; 2001 Aug; 26(4):297-300. PubMed ID: 12536717
[TBL] [Abstract][Full Text] [Related]
64. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.
Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2002 Oct; 69(4):205-12. PubMed ID: 12431239
[TBL] [Abstract][Full Text] [Related]
65. Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers.
Schoser BG; Blottner D; Stuerenburg HJ
Acta Neurol Scand; 2002 Apr; 105(4):309-13. PubMed ID: 11939944
[TBL] [Abstract][Full Text] [Related]
66. Application of Newly Developed Tissue-arrays to Study EMMPRIN (CD147) Expression in Malignant Non-Hodgkin Lymphoma.
Thorns C; Noack F; Feller AC; Merz H; Stöcker W; Mueller-Kunert E; Bernd HW
Cancer Genomics Proteomics; 2004; 1(1):45-52. PubMed ID: 31394617
[TBL] [Abstract][Full Text] [Related]
67. Measurement of matrix metalloproteinase activities in the medium of cultured synoviocytes using zymography.
Troeberg L; Nagase H
Methods Mol Biol; 2003; 225():77-87. PubMed ID: 12769476
[No Abstract] [Full Text] [Related]
68. Medulloblastoma displays distinct regional matrix metalloprotease expression.
Vince GH; Herbold C; Klein R; Kühl J; Pietsch T; Franz S; Roosen K; Tonn JC
J Neurooncol; 2001 Jun; 53(2):99-106. PubMed ID: 11716074
[TBL] [Abstract][Full Text] [Related]
69. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma.
Hazar B; Polat G; Seyrek E; Bağdatoğlğlu O; Kanik A; Tiftik N
Int J Clin Pract; 2004 Feb; 58(2):139-43. PubMed ID: 15055861
[TBL] [Abstract][Full Text] [Related]
70. Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury.
Bankov K; Döring C; Ustaszewski A; Giefing M; Herling M; Cencioni C; Spallotta F; Gaetano C; Küppers R; Hansmann ML; Hartmann S
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671543
[TBL] [Abstract][Full Text] [Related]
71. Current status of prognostication in classical Hodgkin lymphoma.
Venkataraman G; Mirza MK; Eichenauer DA; Diehl V
Br J Haematol; 2014 May; 165(3):287-99. PubMed ID: 24494650
[TBL] [Abstract][Full Text] [Related]
72. [Aortic calcification and matrix metalloproteinases].
Cui X; Wang S; Guo A
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):347-9. PubMed ID: 11866933
[TBL] [Abstract][Full Text] [Related]
73. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.
Taylor PM; Woodfield RJ; Hodgkin MN; Pettitt TR; Martin A; Kerr DJ; Wakelam MJ
Oncogene; 2002 Aug; 21(37):5765-72. PubMed ID: 12173047
[TBL] [Abstract][Full Text] [Related]
74. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function.
Toole BP
Curr Top Dev Biol; 2003; 54():371-89. PubMed ID: 12696756
[No Abstract] [Full Text] [Related]
75. [Activity of nonspecific esterase and acid phosphatase in Berezovsky-Sternberg giant cells in patients with lymphogranulomatosis].
Press BO; Shvetsova FV
Probl Gematol Pereliv Krovi; 1975 Oct; 20(10):22-5. PubMed ID: 1197216
[No Abstract] [Full Text] [Related]
76. Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients.
Silva BO; Medeiros JW; Albuquerque GS; Valderrama PM; Barbosa AHQ; de Souza JM; Oliveira RS; Morais AL; Neto JDCS; Muniz MTC
J Pediatr (Rio J); 2023; 99(1):59-64. PubMed ID: 35868407
[TBL] [Abstract][Full Text] [Related]
77. Comment on "Fibroblasts in Nodular SclerosingClassical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury"
Aldinucci D; Colombatti A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32028697
[TBL] [Abstract][Full Text] [Related]
78. Interfollicular Classic Hodgkin Lymphoma: Report of a Case and a Brief Review of Literature.
Brannock K; Kahwash SB
Pediatr Dev Pathol; 2024 Mar; ():10935266241236874. PubMed ID: 38468389
[TBL] [Abstract][Full Text] [Related]
79. [Enzyme changes in primary extranodular manifestation of Hodgkin disease and non-Hodgkin lymphomas].
Redlow H; Hempel RD; Gärtner C; Rose H
Radiobiol Radiother (Berl); 1983; 24(3):317-20. PubMed ID: 6635163
[No Abstract] [Full Text] [Related]
80. [Cytochemical reactions in the classification of blood cell populations].
Delgado JE; Estevez ME; Sen L; Diez RA
Medicina (B Aires); 1981; 41 Suppl():101-8. PubMed ID: 7047977
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
